Grassley probes EpiPen rival over its $4,500 list price

first_img Log In | Learn More Grassley probes EpiPen rival over its $4,500 list price [email protected] PRNewsFoto/Sanofi/AP What is it? Ed Silverman GET STARTED Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Pharmalot STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.center_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. By Ed Silverman March 8, 2017 Reprints About the Author Reprints For the second time in recent weeks, a small, privately held drug maker with a piece of the action in two hot markets is being scrutinized by lawmakers over its pricing.In the latest episode, US Senator Chuck Grassley (R-Iowa) wants Kaleo to explain why it set a $4,500 list price for the Auvi-Q allergic reaction device that is competing with EpiPen. The move is actually part of a complicated pricing strategy that may appeal to some consumers, but not so much to insurers. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED What’s included? @Pharmalot Tags drug pricingpharmaceuticalsSTAT+last_img read more